-
Tytuł:
-
Role of [ F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors.
-
Autorzy:
-
Magi L; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, 00189, Rome, Italy.; Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Prosperi D; Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, 00189, Rome, Italy.
Lamberti G; Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Marasco M; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, 00189, Rome, Italy.
Ambrosini V; Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Rinzivillo M; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, 00189, Rome, Italy.
Campana D; Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Gentiloni G; Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, 00189, Rome, Italy.
Annibale B; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, 00189, Rome, Italy.; Department of Medical-Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Signore A; Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, 00189, Rome, Italy.; Department of Medical-Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Panzuto F; Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, 00189, Rome, Italy. .; Department of Medical-Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy. .
-
Źródło:
-
Endocrine [Endocrine] 2022 May; Vol. 76 (2), pp. 484-490. Date of Electronic Publication: 2022 Feb 11.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Feb. 1996- : Totowa, NJ : Humana Press
Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994-
-
MeSH Terms:
-
Neuroendocrine Tumors*/pathology
Organometallic Compounds*/therapeutic use
Pancreatic Neoplasms*/pathology
Fluorodeoxyglucose F18 ; Humans ; Intestinal Neoplasms ; Positron Emission Tomography Computed Tomography ; Retrospective Studies ; Stomach Neoplasms
-
References:
-
Neuroendocrinology. 2016;103(2):153-71. (PMID: 26742109)
J Clin Med. 2019 Jul 13;8(7):. (PMID: 31337043)
Neuroendocrinology. 2016;103(2):125-38. (PMID: 26758972)
Contrast Media Mol Imaging. 2018 Feb 26;2018:2340389. (PMID: 29681780)
J Nucl Med. 2017 Jan;58(1):91-96. (PMID: 27516446)
Clin Cancer Res. 2008 Dec 1;14(23):7798-803. (PMID: 19047107)
PLoS One. 2017 Jun 23;12(6):e0179445. (PMID: 28644861)
J Hepatobiliary Pancreat Sci. 2020 Jul;27(7):414-420. (PMID: 32196985)
Neuroendocrinology. 2017 Mar 30;105(3):212-244. (PMID: 28355596)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Oncologist. 2018 Feb;23(2):186-192. (PMID: 29118267)
J Nucl Med. 2014 Nov;55(11):1786-90. (PMID: 25286923)
J Nucl Med. 2021 Jun 1;62(6):808-815. (PMID: 33067340)
Endocrine. 2017 Sep;57(3):494-502. (PMID: 28726181)
J Nucl Med. 2016 Jan;57(1):34-40. (PMID: 26471695)
CA Cancer J Clin. 2018 Nov;68(6):471-487. (PMID: 30295930)
Neuroendocrinology. 2009;90(2):159-61. (PMID: 19713708)
Neuroendocrinology. 2018;107(4):375-386. (PMID: 30300897)
J Clin Med. 2019 Jun 25;8(6):. (PMID: 31242670)
Virchows Arch. 2006 Oct;449(4):395-401. (PMID: 16967267)
Dig Liver Dis. 2011 Mar;43 Suppl 4:S356-60. (PMID: 21459341)
Clin Cancer Res. 2010 Feb 1;16(3):978-85. (PMID: 20103666)
Virchows Arch. 2007 Oct;451(4):757-62. (PMID: 17674042)
Cancers (Basel). 2021 Oct 15;13(20):. (PMID: 34680321)
Cancer. 2008 Jul 15;113(2):256-65. (PMID: 18506737)
Pancreatology. 2019 Dec;19(8):1067-1073. (PMID: 31587962)
Neuroendocrinology. 2014;100(4):293-9. (PMID: 25301162)
JAMA Oncol. 2017 Oct 01;3(10):1335-1342. (PMID: 28448665)
J Clin Endocrinol Metab. 2017 May 1;102(5):1486-1494. (PMID: 28324047)
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. (PMID: 25452219)
Cancer. 2008 Jun;112(11):2447-55. (PMID: 18383518)
-
Contributed Indexing:
-
Keywords: Grading; Management; PET; Pancreatic endocrine tumors; Prognosis
-
Substance Nomenclature:
-
0 (Organometallic Compounds)
0Z5B2CJX4D (Fluorodeoxyglucose F18)
-
SCR Disease Name:
-
Gastro-enteropancreatic neuroendocrine tumor
-
Entry Date(s):
-
Date Created: 20220212 Date Completed: 20220506 Latest Revision: 20220716
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC9068639
-
DOI:
-
10.1007/s12020-022-03000-3
-
PMID:
-
35149933
-
Purpose: Since the role of [ 18 F]FDG PET/CT in low-grade gastroenteropancreatic (GEP) neuroendocrine neoplasia (NET) is not well established, this study was aimed to evaluate the role of [ 18 F]FDG PET/CT in grade 1 (G1) GEP-NETs.
Methods: This is a retrospective study including patients with G1 GEP-NETs who underwent [ 18 F]FDG PET/CT.
Results: 55 patients were evaluated, including 24 (43.6%) with pancreatic NETs and 31 (56.4%) with gastrointestinal NETs. At the time of diagnosis, 28 (51%) patients had metastatic disease, and 50 (91%) patients were positive by 68-Ga sstr PET/CT. Overall, 27 patients (49%) had positive findings on [ 18 F]FDG PET/CT. Following [ 18 F]FDG PET/CT, therapeutic management was modified in 29 (52.7%) patients. Progression-free survival was longer in patients with negative [ 18 F]FDG PET/CT compared with positive [ 18 F]FDG PET/CT (median PFS was not reached and 24 months, respectively, p = 0.04). This significance was particularly evident in the pancreatic group (p = 0.008).
Conclusions: Despite having low proliferative activity, approximately half of GEP-NETs G1 showed positive [ 18 F]FDG PET/CT, with a corresponding negative impact on patients' clinical outcomes. These data are in favor of a more "open" attitude toward the potential use of [ 18 F]FDG PET/CT in the diagnostic work-up of G1 GEP-NETs, which may be used in selected cases to detect those at higher risk for an unfavorable disease course.
(© 2022. The Author(s).)
